Brief: Bergenbio Announces Positive Interim Clinical And Translational Data From Phase II Trial Of Bemcentinib In Combination With Keytruda
25/06/2020 18:21
June 25 (Reuters) - Bergenbio ASA BGBIO.OL :
* BERGENBIO ANNOUNCES POSITIVE INTERIM CLINICAL AND
TRANSLATIONAL
DATA FROM PHASE II TRIAL OF BEMCENTINIB IN COMBINATION WITH
KEYTRUDA ® IN CHECKPOINT INHIBITOR REFRACTORY NSCLC PATIENTS
Source text for Eikon: ID:nWkr9krC0M
Further company coverage: BGBIO.OL
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncoinvent ASA
See all newsBrief: Oncoinvent To Raise Up To NOK 140 Million In Private Placement
Brief: Oncoinvent H1 Operating Loss NOK 69 Mln
Brief: Oncoinvent Secures New Patent Expanding Protection For Radspherin
Brief: Oncoinvent's Shares To Be Consolidated In Ratio Of 100:1
Brief: Oncoinvent To Increase Share Capital In Connection With Settlement Of Underwriting Fee